Reaction profile
The FDA adverse-event record for pulmonary fibrosis
51 FDA reports name pulmonary fibrosis, a lower-volume reaction in the CVM extract (VeDDRA 2259). Plate stamps and neighbourhood peers follow.
- #1731 of 2,481
- by report volume (all reactions)
- 51
- reports citing this reaction
- 80.4%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Pulmonary fibrosis has 51 reports now versus 49 in that prior snapshot: 2 more (4.1%).
- Report change
- +2
- Death-coded reports
- +2
- Death-coded share
- +0.8 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Pulmonary fibrosis changesFDA AER · VeDDRA plate
Code 2259 VOL-LOW
VOL-LOW · DEATH-HOT · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-LOW 51 reports
- DEATH-HOT 80.4%
- MID-PACK #1731/2481
- PHOTO-FINISH Application site scar
- SPECIES-DOG Dog · 42
- DRUG-LEAD Rabacfosadine · 14
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Application site scar (±0 reports)
Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.
Lower-volume neighbourhood around Pulmonary fibrosis
Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.
Pulmonary fibrosis: high death-coded share in the FDA AER plate
Signature read: Pulmonary fibrosis's 80.4% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 51 named reports in the openFDA extract. Death-coded share is upper-third: 41 of 51 reports (80.4% of named reports). Nearest volume peer: Application site scar (±0 reports). Lead species Dog (42). Lead co-reported drug Rabacfosadine (14).
Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Pulmonary fibrosis, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (51 here).
Similar death-coded share
Nearest other reactions by death-coded share (80.4% here), distinct from the volume row.
What to do with this reaction
- Compare Pulmonary fibrosis's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →